{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 12,
  "pageCount": 58,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "testimonial",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.",
  "elementsJson": [
    "bar_chart_100pct",
    "quote_block",
    "photo"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/12",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbe-5b48b69214d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.2,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Stacked bar chart showing 5%, 36%, 34%, 26% distribution",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8cfe2ef-4394-489a-bbcd-7a13fd7e7d9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: *Survey question: In the next 5 years (2022-27), what's your view on China clinical trial growth rate compared with historical growth (2016-21)?",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf9c0d75-8b36-4990-a726-1dffc7ac75b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 60%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbe-61c46df7decf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.5,
        "x": 0.45,
        "y": 0.3
      },
      "kind": "quote",
      "text": "Market feedback: quotes from CEO, R&D Lead, and CEO regarding trial growth and innovation.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71dff259-90ce-4200-8bcd-d27196891792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "The industry is going to keep growing fast because its foundation is solid. We are ready to apply theories into applications among various TAs, our population provides a great base for research, and pioneers have validated the business model for new entrants... - CEO, a Chinese biotech, Oct. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbe-5d9677406766",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80429f63-34cf-4ae5-9f9f-77a12d30f3e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "Perspectives on clinical trial number growth rate in 2022-27*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f922de5c-240d-469d-b4e7-b6b6915ba5a5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "60%",
      "numberKind": "percent",
      "actionTitle": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth",
      "calloutText": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth",
      "numberScale": null,
      "numberValue": 60,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [
    {
      "name": "testimonial",
      "slug": null,
      "matchId": "1f4e6984-0a6f-46f8-9e35-b21b5bd44395",
      "evidence": "Use of direct quotes from industry experts to support the quantitative data.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}